Martin Jacko is the founder of Aperture Therapeutics, a startup developing ASO (Antisense Oligonucleotide) based therapies for neurodegenerative diseases like ALS. Aperture's approach is unique in how they are guided by genetic profiles of individuals who are naturally resilient to neurodegenerative diseases. Martin joins Sam Tabone and Brom Rector to discuss (5:00) - Aperture origin story

(10:00) - history of trying to cure ALS, why 150 attempts failed

(25:00) - why neuro is hot right now - genetic medicine

(33:00) - why 23 and me failed

(41:00) - how genetics lead to personalized medicine

(53:00) - martin’s advice for founders https://www.aperturetx.com/